As of 2026, Artificial Intelligence (AI) is bringing unprecedented innovation to the biopharmaceutical industry, fundamentally transforming the paradigm of drug development. Unlike traditional methods that have historically required decades and immense costs, AI demonstrates exceptional capabilities in rapidly identifying key disease targets by analyzing vast genomic and proteomic data, designing optimal candidate compounds, and predicting drug toxicity and efficacy in advance. The advancement of these AI-driven technologies is dramatically shortening the drug development process, instilling new hope for humanity's fight against intractable diseases. Beyond drug development, AI is ushering in an era of personalized precision medicine by integrating and analyzing extensive healthcare data, including individual genomic information, lifestyle habits, and medical records. AI predicts patient responses to specific drugs, reduces the risk of side effects, and proposes optimal treatment plans, thereby minimizing unnecessary procedures and drug misuse. Furthermore, in clinical trials, AI plays a crucial role in selecting suitable patients and enhancing the accuracy of data analysis, leading to more efficient and reliable clinical outcomes and accelerating the market launch of new drugs. The AI-driven bio-revolution is expected to contribute significantly not only to treating diseases but also to extending human health spans and improving quality of life. However, this innovation comes with important challenges such as data privacy issues, the transparency of AI algorithms, and the establishment of ethical guidelines for new technologies. Close collaboration among scientists, medical professionals, ethicists, and policymakers is essential, and it is time to explore sound development directions for AI bio-technology under the ultimate goal of enhancing human welfare. In the future, AI will become even more sophisticated, bringing about unpredictable medical innovations. ────────────────────────────